Brentuximab Vedotin Shows Activity in Cutaneous T-Cell Lymphomas

Share this content:
Brentuximab vedotin demonstrated activity in treatment-refractory or advanced mycosis fungoides and Sézary syndrome.
Brentuximab vedotin demonstrated activity in treatment-refractory or advanced mycosis fungoides and Sézary syndrome.

Brentuximab vedotin demonstrated significant clinical activity in patients with treatment-refractory or advanced mycosis fungoides and Sézary syndrome with a wide range of CD30 expression levels, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

Mycosis fungoides and Sézary syndrome are types of cutaneous T-cell lymphomas in which the lymphocytes become malignant and affect the skin, according to the National Cancer Institute.

CD30 expression levels in patients with these diseases are quite variable, as opposed to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Therefore, researchers sought to evaluate the clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, in patients with these lymphomas.

For the phase 2 study, researchers enrolled and treated 32 patients with mycosis fungoides or Sézary syndrome with brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks for a maximum of 16 doses. Patients had CD300 expression levels ranging from negligible levels to 100%.

Results showed that objective global response was observed in 70% of 30 evaluable patients (90% CI: 53, 83). Researchers found that those with a CD30 expression less than 5% were less likely to achieve a global response compared with those with 5% or greater CD30 expression (P<0.005).

RELATED: Identifying Lymphoma Survivors at Higher Risk for LVSD, Heart Failure

In regard to safety, the most common treatment-related adverse event was peripheral neuropathy.

The authors note that additional biomarker studies are warranted to design combination therapies with brentuximab vedotin to be used in patients with these cutaneous T-cell lymphomas.

Reference

  1. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200.JCO.2014.60.3969.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters